Navigation Links
FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer
Date:4/29/2010

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC).  PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.

The FDA approval of PROVENGE is a testament to the courage of the patients and researchers who participated in our studies and is the culmination of nearly 15 years of research and development by our dedicated employees," said Mitchell H. Gold, M.D., president and chief executive officer of Dendreon.  "The approval of PROVENGE is a significant step towards realizing our mission of transforming the lives of patients with cancer, and it also marks Dendreon's transformation into a commercial enterprise, ready to support the successful launch of the first personalized treatment for cancer."

Dendreon intends to make PROVENGE available through approximately 50 centers, all of which were approved PROVENGE clinical trial sites, and expects to increase capacity over the next year. The increased capacity will be a result of the anticipated licensure of its expanded New Jersey, Atlanta, Georgia and Orange County, Calif. facilities in mid-2011.

"The approval of PROVENGE, th
'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014  In part four ... a hospital pharmacy as a strategic asset, Mary ... leader for Cardinal Health,s Innovation Delivery Solutions business, discusses ... benefit both hospitals and patients. "Every hospital ... part of their job in a value-based healthcare world," ...
(Date:8/29/2014)... Research and Markets  has announced the ... Devices Market 2014-2018" report to their offering. ... cells that connect, support, or surround bones. There are ... ligaments, cartilage, fascia, and other fibrous tissues. Repetitive use, ... age result in wear and tear in these tissues. ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Safety and Compliance Services Industry (U.S.): ... Revenue Forecasts to 2021, NAIC 541380 ... .html Testing Laboratories, Safety ...
Breaking Medicine Technology:Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 2Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 3Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 4Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 5Testing Laboratories, Safety and Compliance Services Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021, NAIC 541380 6
... (LSE: SHP, Nasdaq: SHPGY ), the global specialty ... Administration (FDA) approved the use of once-daily INTUNIV® (guanfacine) ... treatment of attention deficit hyperactivity disorder (ADHD) in children and ... treatment program. The approval is based on results from a ...
... specialist in genome customization and subsidiary of Cellectis (Alternext: ... custom TALEN(1). Recognized as a pioneer in ... Cellectis bioresearch brings today the life sciences community a ... of cell. The service will start with ...
Cached Medicine Technology:FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 2FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 3FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 4FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 5FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents 6Cellectis bioresearch Makes Genome Engineering Affordable for All Users 2
(Date:8/29/2014)... August 29, 2014 Champion boxers Laila ... disease by appearing on the annual MDA Show of ... 31, 9/8c on ABC television stations across the country. ... current host of “All In, with Laila Ali," will ... Boy during the Muscular Dystrophy Association's nationally broadcast show. ...
(Date:8/29/2014)... 30, 2014 Developed as a nod ... quality Canada Goose products offer the mobility, ... on Arctic runways. The company’s Canada Goose Chilliwack ... the current market. Additionally, the firm has unveiled its ... , At present, all high quality Chilliwack bombers ...
(Date:8/29/2014)... According to a CNN article, entitled ... (8/25), a new study found that those states who ... a significant decrease in the number of painkiller overdoses ... year period, and comparing various states with and without ... there was about a 25% decrease in painkiller prescription ...
(Date:8/29/2014)... As reported by CNN.com in the article ... process of admitting that you need help for a prescription ... and highlights the fact that if you simply try to ... overwhelmed by all of the information that is available online. ... through, it is still possible to get help. The statistics ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 According to new ... But Not Peer Pressure, Key to Prescription Drug Misuse Among ... primary focus for 18-29 year olds when it comes to ... the for this age group the real problem which influences ... drug associations and recreational use of them to have fun ...
Breaking Medicine News(10 mins):Health News:Champion Boxers Fight Back Against Muscle Disease 2Health News:Champion Boxers Fight Back Against Muscle Disease 3Health News:New Designs Of Canada Goose Chilliwack Bombers From DoudouneCanadienneGoosePasCher.fr 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 2Health News:Overdoses on Painkillers Decreased in States With Medical Marijuana 3Health News:What to Know When Seeking Drug Addiction Help 2Health News:What to Know When Seeking Drug Addiction Help 3Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 2Health News:Peer Pressure Irrelevant in Prescription Drug Abuse for Young Adults 3
... pulmonary disease, research shows , , WEDNESDAY, March 11 ... why one-quarter of smokers develop chronic obstructive pulmonary ... the serious breathing problem, U.S. researchers conclude. , ... long-term heavy smokers with and without COPD. Previous ...
... Calif., March 11 Solta Medical, Inc. (Nasdaq: ... today announced that Silicon Valley Bank, a member company of ... the company with a $9 million credit facility. "We ... our ability to pursue our strategic initiatives in the aesthetic ...
... The recent delivery of octuplets in Los Angeles was ... not obscure the risk of high-order multiple pregnancy. As ... outcome, with risk for mother and babies. With ... mostly preventable. Pacific Fertility Center has been taking steps to ...
... one altruistic living donor, study explains, , , WEDNESDAY, March ... man stepped forward, willing to give one of his ... people had received new kidneys from that one remarkable ... first nonsimultaneous, extended altruistic-donor (NEAD) chain. The woman who ...
... in smog heightens lung, heart risks, report finds , , WEDNESDAY, ... each year from lung disease caused by atmospheric ozone, a ... living be in hot, dry cities such as Los Angeles, ... of Los Angeles may face a 25 percent to 30 ...
... Texas, March 11 The Coalition for Ethical Imaging ... diagnostic imaging practices in Texas, has announced its support ... and its companion bill in the House, House Bill ... enhance diagnostic imaging patient care and safety in the ...
Cached Medicine News:Health News:Solta Medical, Inc. Secures $9M Credit Facility from Silicon Valley Bank 2Health News:Octuplets Fiasco Could Have Been Prevented 2Health News:Octuplets Fiasco Could Have Been Prevented 3Health News:Living Kidney Donation Chains May Help More Get Transplants 2Health News:Living Kidney Donation Chains May Help More Get Transplants 3Health News:Ozone Pollution Taking Toll on American Lives 2Health News:Ozone Pollution Taking Toll on American Lives 3Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 2Health News:The Coalition for Ethical Imaging Announces Support for Diagnostic Imaging Bills Introduced in Texas Legislature 3
The Livewire steerable electrophysiology catheter is uniquely designed with an ergonomic handle and patented steering mechanism to provide smooth, precise catheter tip movement, even during lengthy e...
... HP catheters feature 20 bipolar-spaced electrodes ... highest degree of mapping resolution in ... via a 20-pole catheter enables more ... than with 10-pole catheter systems. The ...
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
... 70 RF Generator introduces maximum ... every day, in every ablation ... and the CARTO EP Navigation ... Catheter provide clinicians with a ...
Medicine Products: